1800-272-662
Shopping Cart 0
countryflagAU
Login

Elixinol Wellness Ltd

Healthcare AU EXL

0.008AUD
-(-%)

Last update at 2026-03-12T02:28:00Z

Day Range

0.0080.009
LowHigh

52 Week Range

0.0080.03
LowHigh

Fundamentals

  • Previous Close 0.008
  • Market Cap3.31M
  • Volume153314
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.40700M
  • Revenue TTM15.50M
  • Revenue Per Share TTM0.06
  • Gross Profit TTM 5.71M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.03500M -5.31100M -7.50400M -10.56900M -17.09000M
Minority interest - - - - -
Net income -5.50000M -1.72200M -7.50700M -10.57100M -17.02500M
Selling general administrative - 5.48M 6.17M 8.08M 12.95M
Selling and marketing expenses - 2.39M 1.82M 2.29M 3.68M
Gross profit 0.75M 5.36M -1.80400M 3.24M 4.90M
Reconciled depreciation - 1.04M 0.60M 0.72M 2.30M
Ebit -4.97600M -5.05200M -7.40300M -9.01200M -11.66800M
Ebitda -4.10700M -4.01000M -6.80600M -8.29100M -10.17800M
Depreciation and amortization 0.87M 1.04M 0.60M 0.72M 1.49M
Non operating income net other - - - - -
Operating income -4.97600M -3.46800M -6.43300M -9.01200M -11.66800M
Other operating expenses 20.48M 18.42M 14.73M 17.06M 24.95M
Interest expense 0.49M 0.21M 0.10M -0.04900M 5.42M
Tax provision - -3.58900M 0.00300M 0.00200M -0.06500M
Interest income - 0.03M 0.21M 0.02M 0.00800M
Net interest income - -0.18200M 0.11M -0.04900M -0.06300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.53500M -3.58900M 0.00300M 0.00200M -0.06500M
Total revenue 15.50M 14.96M 8.27M 7.05M 9.34M
Total operating expenses 5.73M 8.82M 9.88M 13.24M 20.50M
Cost of revenue 14.75M 9.60M 10.07M 3.82M 4.44M
Total other income expense net -1.05900M -1.84300M -1.04200M -1.55700M -5.42200M
Discontinued operations - - - - -
Net income from continuing ops - -1.72200M -7.50700M -10.57100M -27.85300M
Net income applicable to common shares - -1.72200M -7.50700M -10.57100M -17.02500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 15.96M 18.45M 11.71M 13.48M 25.33M
Intangible assets 2.02M 4.81M - 0.15M 0.46M
Earning assets - - - - -
Other current assets 0.45M 0.91M 2.08M 0.17M 0.17M
Total liab 8.51M 8.42M 5.25M 4.33M 6.25M
Total stockholder equity 7.45M 10.03M 6.46M 9.16M 19.08M
Deferred long term liab - - - - -
Other current liab 1.67M 1.87M 1.64M 1.35M 1.10M
Common stock 229.88M 228.29M 222.57M 218.12M 218.06M
Capital stock - - - 218.12M 218.06M
Retained earnings -233.29500M -227.87500M -226.15300M -218.64600M -208.07500M
Other liab - - - - -
Good will 3.13M 1.37M - - 0.00000M
Other assets - - 0.00000M 0.08M 0.18M
Cash 1.41M 1.08M 0.71M 2.86M 12.65M
Cash and equivalents - - - - -
Total current liabilities 6.64M 4.99M 4.99M 3.44M 4.71M
Current deferred revenue 0.05M - 0.52M - 1.07M
Net debt 2.54M 0.86M 0.55M -0.96000M -9.93400M
Short term debt 3.40M 1.30M 1.07M 1.02M 1.18M
Short long term debt - - - 0.32M 0.43M
Short long term debt total 3.95M 1.94M 1.26M 1.90M 2.71M
Other stockholder equity - - - 9.09M 9.09M
Property plant equipment - - - 1.11M 2.48M
Total current assets 5.70M 7.18M 8.18M 9.31M 19.59M
Long term investments - - - 2.83M 2.62M
Net tangible assets - - - 9.01M 18.61M
Short term investments - - - 0.17M 0.17M
Net receivables 1.19M 1.30M 1.72M 3.97M 2.97M
Long term debt - - - 0.25M 0.25M
Inventory 2.66M 3.89M 3.66M 1.74M 2.20M
Accounts payable 1.52M 1.82M 1.76M 1.08M 1.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 10.87M 9.61M 10.04M 9.68M 9.09M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 3.67M 2.35M 0.08M 0.18M
Deferred long term asset charges - - - - -
Non current assets total 10.26M 11.27M 3.54M 4.17M 5.74M
Capital lease obligations - - - 1.33M 2.04M
Long term debt total - - - 0.82M 1.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.06600M -1.04400M -0.86900M -0.01000M
Change to liabilities - - - -0.90300M -0.61400M
Total cashflows from investing activities -0.21600M -0.06600M -1.04400M -0.86900M 0.17M
Net borrowings - 0.86M 0.30M -0.75700M -1.04700M
Total cash from financing activities 3.65M 3.92M 1.61M -0.75700M -1.15700M
Change to operating activities - - - 0.23M 0.35M
Net income -5.50000M -1.72200M -7.50700M -10.57100M -27.85300M
Change in cash 0.33M 0.37M -2.15600M -9.78500M -15.09400M
Begin period cash flow 1.08M 0.71M 2.86M 12.65M 27.74M
End period cash flow 1.41M 1.08M 0.71M 2.86M 12.65M
Total cash from operating activities -3.21400M -3.46900M -2.75800M -9.85000M -14.07100M
Issuance of capital stock - 4.66M 2.25M - -
Depreciation 0.87M 1.04M 0.60M 0.72M 1.49M
Other cashflows from investing activities 0.00200M 2.27M -1.22400M -0.85700M 0.46M
Dividends paid - - - - -
Change to inventory 1.23M 1.73M 0.47M 0.23M -0.24400M
Change to account receivables 0.42M 0.54M 1.37M 0.14M -2.01400M
Sale purchase of stock - -0.56400M -0.19900M - -0.11000M
Other cashflows from financing activities -0.30500M -1.04100M -0.73800M -0.75700M -1.04700M
Change to netincome - - - 1.52M 4.02M
Capital expenditures 0.07M 0.06M 0.02M 0.01M 0.29M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.75M 1.49M 1.97M 0.39M 0.41M
Stock based compensation - 0.05M 0.68M - -
Other non cash items 0.66M -4.28300M 1.51M 9.85M 26.36M
Free cash flow -3.27900M -3.52900M -2.77500M -9.86200M -14.36300M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EXL
Elixinol Wellness Ltd		 - -% 0.008 - 125.00 0.21 0.44 0.36 -0.7144
AFP
Aft Pharmaceuticals Ltd		 - -% 3.00 23.08 19.88 1.35 3.81 1.72 13.67
VLS
Vita Life Sciences Ltd		 -0.02 0.80% 2.48 13.89 42.73 1.46 2.42 1.24 6.53
SNT
Syntara Ltd		 -0.001 3.33% 0.03 - 20.45 6.32 4.62 6.32 -2.1607
MVP
Medical Developments International Ltd		 0.005 1.23% 0.41 - 166.67 1.14 0.83 0.75 11.48

Reports Covered

Stock Research & News

View All

Profile

Elixinol Wellness Limited, a holding company, produces and sells human nutrition, human wellness, pet wellness, and superfood ingredients in Australia, the Americas, and internationally. The company offers its products under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributes its products through grocery, wholesale, and e-commerce channels for white label customers, as well as food, beverage, and beauty manufacturers. In addition, the company engages in the manufacture and distribution of hemp-derived cannabidiol (CBD) products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is based in Newtown, Australia.

Elixinol Wellness Ltd

51 - 53 Riversdale Road, Newtown, VIC, Australia, 3220

Key Executives

Name Title Year Born
Mr. Ronald Dufficy BEC, FCPA Interim Global Chief Exec. Officer NA
Ms. Josephine Lorenz Global CFO & Group Financial Controller NA
Glen Zurcher Account Director of Investor Relations Department NA
Ms. Teresa Cleary Gen. Counsel & Company Sec. NA
Mr. Rob Hasselman Pres of Americas NA
Ms. Beata Silber Global Head of R&D and Innovation NA
Ms. Kim Bradley-Ware Joint Company Sec. NA
Mr. Ronald Dufficy BEC, FCPA Group CEO, MD & Director NA
Ms. Josephine Lorenz Global CFO, Group Financial Controller & Joint Company Secretary NA
Mr. Rob Hasselman President of Americas NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.